Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

ment expenses increased 6 percent to $63.7 million from $60.3 million for the corresponding period in 2010.

Increase in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments.  Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.  The increase in fair value of the Symphony Icon purchase liability was $2.3 million and $1.1 million for the three months ended September 30, 2011 and 2010, respectively, and was $5.2 million and $1.1 million for nine months ended September 30, 2011 and 2010, respectively.  

General and Administrative Expenses:  General and administrative expenses for the three months ended September 30, 2011 decreased 18 percent to $4.1 million from $4.9 million for the corresponding period in 2010.  The decrease was primarily attributable to decreased personnel costs.  For the nine months ended September 30, 2011, general and administrative expenses decreased 14 percent to $13.3 million from $15.5 million for the corresponding period in 2010.  

Consolidated Net Loss:  Net loss for the three months ended September 30, 2011 was $26.1 million, or $0.08 per share, compared to a net loss of $27.5 million, or $0.08 per share, in the corresponding period in 2010.  Net loss for the nine months ended September 30, 2011 was $82.4 million, or $0.24 per share, compared to a net loss of $78.8 million, or $0.27 per share, for the corresponding period in 2010.  For the three and nine months ended September 30, 2011, net loss included non-cash, stock-based compensation expense of $1.4 million and $4.4 million, respectively.  For the three and nine months ended September 30,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Research and Markets has announced the addition ... Disease: A Comprehensive Analysis and Market Study of New ... This report is a comprehensive analysis ... minimally-invasive biomarkers in Alzheimer,s disease, which have been ,functionally ... AD drug pipeline, and applicable commercial AD diagnostics. ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
Breaking Medicine Technology:Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2Implementing a Strategic Thought Leader Management & Engagement System 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Findings from an international,multicenter, randomized, double-blind, placebo-controlled Phase ... of moderate to severe,plaque psoriasis will be presented ... the World Congress of Dermatology, which takes place ... Aires, Argentina. The presentation, entitled CNTO 1275 ...
... Study Will Assess Drug,s Benefit, Alone and With Lipitor(R), ... Cholesterol and Triglycerides -, HAYWARD, Calif., Sept. 25 ... and development of novel,therapeutics for diabetes and related metabolic ... 2 trial of MBX-8025 in overweight or,obese patients with ...
Cached Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:9/2/2014)... At the 50th Annual Mr. Olympia ... an exhibitor at the Las Vegas Convention Center South ... 89109 Booth #374 Sept 19th and 20th 10am-5PM. ... through exercise, diet and supplementation. They pride themselves on ... tools for all Prosupps customers to reach their personal ...
(Date:9/2/2014)... Tuesday 2 September 2014: A simple awareness campaign ... (AF), according to research presented at ESC Congress today ... said: "Atrial fibrillation (AF) is the most common cardiac ... by three-fold and the risk of stroke risk by ... 1 of 4 cases. However, AF is often overlooked ...
(Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
(Date:9/2/2014)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a forward-thinking ... Avon Health Center, a long-time NOVAtime 3000 customer ... Time and Attendance / Workforce Management solution ... the NT7000 . , Avon Health Center in ... nursing facility that provides short-term rehabilitation, long-term care, ...
(Date:9/2/2014)... Productive Dentist Academy, a dental ... State, has been named to Inc. Magazine’s 5000 list ... the third year in a row it has obtained ... astonishing 63 percent growth rate and increased revenues from ... increased its number of employees from eight to 25. ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Dental Management Company Named to Fastest-Growing List Again 2Health News:Dental Management Company Named to Fastest-Growing List Again 3
... through which 3-month-old Jason Wolfe received a lung transplant, while ... // transplant in Ohio. The surgery was possible as a ... compatible to the two babies who were in need of ... lungs were transplanted to Jason, while the heart of Jason ...
... Centers for Disease Control and Prevention said that all samples ... to adamantanes, the class of drugs which is used for ... this class like amantadine and rimantadine are ineffectual for now ... ,The findings were reported in the Journal of the ...
... But now after bringing in changes in their sexual behavior, by ... and using condoms have greatly reduced the number of people suffering ... among women in the age group of 15-24 the prevalence of ... in the age group of 17-29. ,Hence the researcher, ...
... doesn’t seem to rest in the Asian peninsula. A new case ... died at Hasan Sadikin Hospital in the Indonesian town of Bandung.// ... WHO -accredited lab in Hong Kong it will become the 15th ... was a resident of Padalarang in Bandung regency, some150 km south ...
... suspected cases of bird flu have been reported in Iraq’s northern ... result of the disease. The // region’s diagnosis center has admitted ... virus. The Rania region of the north bordering Turkey is reported ... have spread from neighboring Turkey, which has seen four deaths and ...
... Severe earthquakes can result due to tectonic plates colliding with ... severe damage can be caused // by the subduction zone. ... The earth's surface is laced with about 51,000 kilometers of ... zones averages a slip of about two inches per year. ...
Cached Medicine News:Health News:Resistant Influenza strains creates panic in US 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: